Patients with PD-L1-expressing gastric or gastroesophageal junction tumors can now be identified for potential treatment with Keytruda using Agilent's assay.
The company's PD-L1 IHC 28-8 pharmDx diagnostic can now be used in cases of urothelial carcinoma and squamous cell carcinoma of the head and neck.
While the company reported an increase in revenues from biopharma partners, this gain was more than offset by lower consumable sales.
As the development of drugs and diagnostics are increasingly beginning to merge, Covance is aiming to dedicate resources to capture market share.
Companion diagnostics developed under the deal will be based on RNAscope and immunohistochemistry technology.
Merck is hoping NanoString's multiplex platform can support gene expression signatures that will better predict which patients will respond to checkpoint inhibitors like its Keytruda.
The partners said they will also combine their respective expertise to offer pharmaceutical companies help in developing companion diagnostics for oncology.
The company said this study marks the first time circulating RNA has been concretely linked to IFN dysregulation in lupus patients.
The company's diagnostic is being used to determine the eligibility of patients with solid tumors to participate in a Phase II trial of entrectinib.
The firm also said that Roche started selling FoundationOne in Israel, Austria, Germany, Switzerland, Brazil, Canada, and Singapore last month.
Even when given the option, not too many authors choose double-blinded peer-review for their manuscripts, ScienceInsider reports.
In PNAS this week: transcriptional read-through in stressed cells, genome stability role for the epigenetic regulator CTCF, and more.
The Save the Redwoods League is teaming with researchers to sequence the genomes of the coast redwood and giant sequoia.
Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.